ChromaDex Corporation (NASDAQ:CDXC) went up by 4.82% from its latest closing price when compared to the 1-year high value of $5.80 and move down -16%, while CDXC stocks collected +10.62% of gains with the last five trading sessions. Press Release reported on 07/07/20 that ChromaDex and the NIH-NIAID Rocky Mountain Laboratories Announce Study to Assess the Therapeutic Potential of Niagen(R) in COVID-19 Animal Models

>> Stay Up To Date On The Best Stocks Under $5 + Market Moving Updates 100% Free. Join Today! <<

ChromaDex Corporation (NASDAQ:CDXC) Worth an Investment?

ChromaDex Corporation (NASDAQ: CDXC) The 36 Months beta value for CDXC stocks is at 1.63, while 5 of the analysts out of 5 who provided ratings for ChromaDex Corporation stocks as a “buy” while 0 as overweight, 0 rated it as hold and 0 as sell. The average price we get from analysts is $7.25 which is $2.06 above current price. CDXC currently has a short float of 6.06% and public float of 36.62M with average trading volume of 490.04K shares.

CDXC Market Performance

CDXC stocks went up by 10.62% for the week, with the monthly jump of 13.38% and a quarterly performance of 43.68%, while its annual performance rate touched 13.12%. The simple moving average for the period of the last 20 days is 12.28% for CDXC stocks with the simple moving average of 25.78% for the last 200 days.

Analysts’ Opinion on ChromaDex Corporation (NASDAQ:CDXC)

Many brokerage firms have already submitted their reports for CDXC stocks, with Oppenheimer repeating the rating for CDXC shares by setting it to “Outperform”. The predicted price for CDXC socks in the upcoming period according to Oppenheimer is $6 based on the research report published on October 16, 2019.

B. Riley FBR, on the other hand, stated in their research note that they expect to see CDXC stock at the price of $7. The rating they have provided for CDXC stocks is “Buy” according to the report published on February 14, 2019.

H.C. Wainwright gave “Buy” rating to CDXC stocks, setting the target price at $8 in the report published on November 27, 2017.

CDXC Stocks 6.11% Far from 50 Day Moving Average

After a stumble in the market that brought CDXC to its low price for the period of the last 52 weeks, ChromaDex Corporation was unable to take a rebound, for now settling with -13.79% of loss for the given period.

The stock volatility was left at 5.24%, however, within the period of a single month, the volatility rate increased by 5.40%, while the shares surge at the distance of +10.62% for the moving average in the last 20 days. In oppose to the moving average for the last 50 days, trading by -3.47% lower at the present time.

In the course of the last 5 trading sessions, CDXC went up by +10.62%, which changed the moving average for the period of 200 days to the total of +20.48% of gains for the stock in comparison to the 20-day moving average settled at $4.48. In addition, ChromaDex Corporation saw 16.01% in overturn over the period of a single year with a tendency to cut further gains.

CDXC Stock Fundamentals

The current profitability levels are settled at -43.20 for the present operating margin and +55.67 for gross margin. The net margin for ChromaDex Corporation stands at -69.45. Total capital return value is set at -80.56, while invested capital returns managed to touch -132.22. Equity return holds the value -149.90%, with -72.70% for asset returns.

Based on ChromaDex Corporation (CDXC), the company’s capital structure generated 8.41 points for debt to equity in total, while total debt to capital is set at the value of 7.76. Total debt to assets is settled at the value of 4.27 with long-term debt to equity ratio rests at -23.61 and long-term debt to capital is 4.24.

The value for Enterprise to Sales is 5.25 with debt to enterprise value settled at 0.01. The receivables turnover for ChromaDex Corporation is 12.74 with the total asset turnover at the value of 1.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.23.